REGENXBIO Inc.(RGNX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

REGENXBIO Inc. (RGNX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RGNX at 26.4/100 on a 32-signal composite quality model, placing it at rank #2,621 of 2,960 stocks — the bottom half of the AI-ranked universe. RGNX scores in the top quartile across revenue growth (92.0). Areas of concern include institutional flow (2.5) and balance sheet strength (5.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), REGENXBIO Inc. reports quarterly revenue of $108.0M, net income of $22.7M, free cash flow of $-63.0M. Top institutional holders of RGNX by reported 13-F value include BlackRock, Redmile Group, STATE STREET, based on the most recent SEC filings. RGNX trades on the Nasdaq exchange and files with the SEC under CIK 1590877. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RGNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REGENXBIO Inc. directly from SEC EDGAR.